We are live on ! Find out more
HALO icon

Halozyme

121 hedge funds and large institutions have $810M invested in Halozyme in 2014 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 45 increasing their positions, 36 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

61% more capital inflows, than outflows

Capital inflows: $56.1M | Capital outflows: $34.8M

26% more call options, than puts

Call options by funds: $13.2M | Put options by funds: $10.5M

25% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 36

1.78% more ownership

Funds ownership: 69.2% → 70.97% (+1.8%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

5% less funds holding

Funds holding: 128 → 121 (-7)

30% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 23

Holders
121
Holders Change
-7
Holders Change %
-5.47%
% of All Funds
3.5%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
16
Increased
45
Reduced
36
Closed
23
Calls
$13.2M
Puts
$10.5M
Net Calls
+$2.75M
Net Calls Change
-$1.19M

HALO Hedge Fund Activity: Q3 2014 in Review

121 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Halozyme (HALO) for Q3 2014, worth a combined $810M — down 5.4% from $857M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of HALO and 16 opened new positions — a net loss of 7 holders — while 36 trimmed existing stakes and 45 added.

The largest buyer was OppenheimerFunds, opening a new position worth an estimated $9.5M. The largest seller was Norges Bank, cutting an estimated $9.8M.

  • 121 institutional investors held Halozyme (HALO) as of Q3 2014, down from 128 in Q2 2014.
  • Funds reported $810M of Halozyme stock for Q3 2014, down 5.4% quarter-over-quarter.
  • 16 funds opened new Halozyme positions in Q3 2014 and 23 closed out, a net change of -7 holders.
  • The largest Halozyme buyer in Q3 2014 was OppenheimerFunds, an estimated $9.5M added.
  • The largest Halozyme seller in Q3 2014 was Norges Bank, an estimated $9.8M sold.

Based on aggregated 13F filings for Q3 2014.